Credit Suisse Group Analysts Give Johnson & Johnson (NYSE:JNJ) a $156.00 Price Target

Credit Suisse Group set a $156.00 target price on Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. BMO Capital Markets started coverage on shares of Yelp in a research note on Wednesday, April 17th. They issued an outperform rating for the company. Barclays upped their price objective on shares of from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the stock an equal weight rating in a research note on Friday, June 21st. Bank of America raised shares of First Horizon National from an underperform rating to a neutral rating and set a $16.00 price objective for the company in a research note on Tuesday, July 16th. Raymond James reaffirmed a reduce rating and issued a $48.00 price objective (up from $45.00) on shares of Hancock Whitney in a research note on Wednesday. Finally, Royal Bank of Canada upped their price objective on shares of Johnson Service Group from GBX 180 ($2.35) to GBX 190 ($2.48) and gave the stock an outperform rating in a research note on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $148.56.

Shares of JNJ opened at $130.31 on Thursday. The stock has a market capitalization of $345.98 billion, a price-to-earnings ratio of 15.93, a P/E/G ratio of 2.20 and a beta of 0.70. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. The company’s fifty day moving average is $138.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.57%. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period in the prior year, the firm earned $2.10 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.92%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

In other news, Director Marillyn A. Hewson bought 3,000 shares of Johnson & Johnson stock in a transaction on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.23% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Marino Stram & Associates LLC raised its holdings in Johnson & Johnson by 1.2% in the second quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock worth $4,485,000 after purchasing an additional 380 shares in the last quarter. Pioneer Trust Bank N A OR raised its holdings in Johnson & Johnson by 0.7% in the second quarter. Pioneer Trust Bank N A OR now owns 42,070 shares of the company’s stock worth $5,860,000 after purchasing an additional 280 shares in the last quarter. Lenox Wealth Management Inc. raised its holdings in Johnson & Johnson by 22.5% in the second quarter. Lenox Wealth Management Inc. now owns 2,405 shares of the company’s stock worth $335,000 after purchasing an additional 441 shares in the last quarter. Davy Asset Management Ltd bought a new position in Johnson & Johnson in the second quarter worth about $9,371,000. Finally, FDx Advisors Inc. raised its holdings in Johnson & Johnson by 3.3% in the second quarter. FDx Advisors Inc. now owns 61,664 shares of the company’s stock worth $8,589,000 after purchasing an additional 1,943 shares in the last quarter. Institutional investors and hedge funds own 66.85% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Insider Trading – What You Need to Know

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.